Product Information
LURASIDONE HCL 40 MG TABLET is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.2095 per EA under NDC 47335068483. Its NADAC has been published 181 times since Apr 19, 2023.
FDA first approved this application on Jan 4, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Lurasidone Hydrochloride market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
47335068483
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LURASIDONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA208066FDA Approved
1/4/2019
TE Code
AB
On Market Since
2/20/2023
Pharmacological Classes
Price Statistics
The NADAC for LURASIDONE HCL 40 MG TABLET has been published 181 times since Apr 19, 2023, and over the history we have for it it has declined 36.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2095 per EA |
|---|---|
| All-time high | $0.3598 (Jun 14, 2023) |
| All-time low | $0.2002 (Nov 20, 2024) |
| 52-week high | $0.2775 |
| 52-week low | $0.2095 |
| Median price | $0.2908 |
| Average price | $0.2851 |
| Largest weekly change | -34.9% (Nov 20, 2024) |
| Weeks tracked | 181 |
| Tracking since | Apr 19, 2023 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lurasidone Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LURASIDONE HCL 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LURASIDONE HCL 40 MG TABLET, manufactured by Sun Pharmaceutical Industries Inc., is $0.2095 per EA (NDC 47335068483), effective Sep 30, 2026.
How has the price of LURASIDONE HCL 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for LURASIDONE HCL 40 MG TABLET has declined 36.9%. It has been tracked across 181 weekly CMS publications since Apr 19, 2023.
What are the highest and lowest recorded NADAC prices for LURASIDONE HCL 40 MG TABLET?
Since Apr 19, 2023, the NADAC for LURASIDONE HCL 40 MG TABLET has ranged from a low of $0.2002 (Nov 20, 2024) to a high of $0.3598 (Jun 14, 2023), with a median of $0.2908 per EA.
Are there cheaper alternatives to LURASIDONE HCL 40 MG TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LURASIDONE HCL 40 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LURASIDONE HCL 40 MG TABLET?
LURASIDONE HCL 40 MG TABLET (NDC 47335068483) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.